Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Teligent, Inc.
The UK-based biotech will license its Pyramid platform to MSD to develop anticancer compounds targeting p53, a key transcription factor dubbed the ‘guardian of the genome’ that has proven highly complex and challenging to drug.
The UK major is acquiring CinCor in a deal that could be worth up to $1.8bn, in return getting hold of its Phase II hypertension candidate, baxdrostat, which offers combination potential with Farxiga.
The UK major has been building its cell therapy portfolio for about three years internally, oncology R&D chief Susan Galbraith tells Scrip, and the purchase of Neogene and its TCR-Ts targeting neoantigens in solid cancers is a logical step.
US FDA inspections lead to warning letters for Aurobindo and Health Plus, while Emergent BioSolutions site escapes nearly unscathed; Sun waits for Halol revisit and Jubilant suffers poor-quality costs as agency investigators resume domestic surveillance post-omicron.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- IGI Laboratories, Inc. (IGI)
- Alveda Pharmaceuticals, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.